NovoCure Limited
NVCRHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the. The company carries a $1.71B market cap, placing it firmly in the small-cap category. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax.
Market Cap
$1.71B
Beta
0.99
P/E (TTM)
—
P/E (Fwd)
-18.20
EPS (TTM)
$-1.26
EPS (Fwd)
$-0.81
ROE
-43.2%
ROA
-9.3%
Cash
$440.6M
Total Debt
$233.4M
Free CF
$22.8M
52W Change
6.8%
Annual Financials
Cash vs Debt
Where NVCR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NVCR finished 3.94% below its 150-day moving average ($15.50) and 0.61% above its 200-day moving average ($14.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVCR overbought or oversold?
At the October 20, 2026 close, NVCR's RSI(14) was 39.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $440.6M in cash comfortably exceeding the $233.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $22.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -43.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $535.0M (2021) to $655.4M (2025), reflecting a 22% increase over the period.
As with any equity investment, NVCR carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing NVCR.